The Avance Biosciences™ team is your trusted partner in navigating the complex analytical landscape of gene editing. Boasting more than 20 years of expertise in pioneering biological assay development and validation, we deliver cutting-edge solutions for evaluating the effectiveness of on-target editing and monitoring off-target editing events in gene-edited T-cells, stem cells, iPSC, sgRNA/mRNA in LIPID, and for both preclinical and clinical research studies.
To meet evolving regulatory requirements, standards and to mitigate risk, researchers utilizing tools such as CRISPR and other gene editing platforms must proactively identify and address off target effects, as well as any unintended modifications at a non-target site such as translocation possibilities.
Fortunately, modern genomic assay platforms — including NGS and ddPCR— provide effective, reliable means to identify off target effects and events, including point mutations, deletions, insertions, inversions, and unexpected translocations.
As an experienced leader and partner in the field of CRISPR gene editing, Avance Biosciences™ provides a comprehensive range of off target services. Using robust GMP/GLP processes — as well as state-of-the-art NGS and ddPCR platforms that optimize scalability, speed, and cost — we help life science researchers take a proactive, strategic approach to off site screening, analysis, and intervention.